Nomination Committee proposal for the Board for the 2012 Annual General Meeting

Huddinge Medivir AB (OMX: MVIR), the research-based specialty pharmaceutical company focused on infectious diseases, has today announced the Nomination Committee’s proposals for a new Board of Directors for the 2012 Annual General Meeting.

The Nomination Committee consists of representatives of the three largest shareholders who agreed to participate on the Committee at the end of the third quarter of 2011, as well as the Chairman of the Board. The composition of the Nomination Committee 2011-2012 has been as follows:

  • Anders Algotsson, chairman and representative for AFA Försäkring
  • Caroline af Ugglas, representative for Skandia Liv
  • Bo Öberg, representative for Class A shareholders
  • Göran Pettersson, chairman of the board, Medivir

The Nomination Committee proposes that the 2012 AGM select a new board by reelecting the Board's current four members, Göran Pettersson, Björn C. Andersson, Anna Malm Bernsten and Ingemar Kihlström, as well as election of two new members, Anders Hallberg and Rolf A. Classon. The proposal also includes reelection of Göran Pettersson, chairman of the board.

Anders Hallberg (b. 1945) has been Professor of Medicinal Chemistry at the Faculty of Pharmacy, Uppsala University, since 1990. From 1990 to 2006 he also had various assignments as a scientific advisor for AstraZeneca and smaller pharmaceutical companies. Before that he was head of the Medicinal Chemistry department at Astra in Lund. From 2006 to 2011 he was rector magnificus at Uppsala University. Anders Hallberg is currently a member of the Swedish government's research advisory committee, the Royal Academy of Sciences and the Royal Academy of Engineering Sciences.

Rolf A. Classon (b. 1945) holds a Master’s degree in Political Science from the University of Gothenburg. He has extensive experience from senior positions in the pharmaceutical and medical technology industries, including Pharmacia and Bayer Diagnostics, and as global CEO of Bayer HealthCare. He has also been a divisional general manager at Swedish Match. Rolf’s current assignments include board assignments at Hill-Rom Corporation (USA), Auxilium Pharmaceuticals (USA), Tecan Group (Switzerland), Fresenius Medical Care (Germany) and Aerocrine AB (Sweden).

A full presentation of the Nomination Committee's proposal will be available in the upcoming notice of the AGM 2012.

For more information about Medivir, please contact:
Rein Piir, EVP Corporate Affairs & IR

Mobil: +46 708 537 292 

About Medivir
Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in the inhibition of polymerases and protease enzymes, as well as drug development in this field, which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is TMC435, a protease inhibitor in phase III clinical development for treatment of hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir’s first product, the unique cold sore product Xerese®/Xerclear®, was launched on the US market in February 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company’s website:


About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links